271 related articles for article (PubMed ID: 36998240)
1. Using Bayesian Evidence Synthesis Methods to Incorporate Real-World Evidence in Surrogate Endpoint Evaluation.
Wheaton L; Papanikos A; Thomas A; Bujkiewicz S
Med Decis Making; 2023 Jul; 43(5):539-552. PubMed ID: 36998240
[TBL] [Abstract][Full Text] [Related]
2. The Validity of Surrogate Endpoints in Sub Groups of Metastatic Colorectal Cancer Patients Defined by Treatment Class and KRAS Status.
Poad H; Khan S; Wheaton L; Thomas A; Sweeting M; Bujkiewicz S
Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358810
[No Abstract] [Full Text] [Related]
3. Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation.
Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H
BMC Cancer; 2019 Jan; 19(1):56. PubMed ID: 30634944
[TBL] [Abstract][Full Text] [Related]
4. Predicting Real-World Effectiveness of Cancer Therapies Using Overall Survival and Progression-Free Survival from Clinical Trials: Empirical Evidence for the ASCO Value Framework.
Lakdawalla DN; Shafrin J; Hou N; Peneva D; Vine S; Park J; Zhang J; Brookmeyer R; Figlin RA
Value Health; 2017; 20(7):866-875. PubMed ID: 28712615
[TBL] [Abstract][Full Text] [Related]
5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
6. Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: A critical review.
Savina M; Gourgou S; Italiano A; Dinart D; Rondeau V; Penel N; Mathoulin-Pelissier S; Bellera C
Crit Rev Oncol Hematol; 2018 Mar; 123():21-41. PubMed ID: 29482777
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of progression-free survival as a surrogate endpoint for overall survival in locally advanced or metastatic differentiated thyroid cancer: a systematic review.
Yang S; Zhan J; Xu X
Endocrine; 2023 Dec; 82(3):491-497. PubMed ID: 37702900
[TBL] [Abstract][Full Text] [Related]
8. Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists.
Methy N; Bedenne L; Bonnetain F
BMC Cancer; 2010 Jun; 10():277. PubMed ID: 20537166
[TBL] [Abstract][Full Text] [Related]
9. The value of surrogate endpoints for predicting real-world survival across five cancer types.
Shafrin J; Brookmeyer R; Peneva D; Park J; Zhang J; Figlin RA; Lakdawalla DN
Curr Med Res Opin; 2016; 32(4):731-9. PubMed ID: 26743800
[TBL] [Abstract][Full Text] [Related]
10. Examining Endpoint Concordance in Clinical Trials and Real-World Clinical Practice to Advance Real-World Evidence Utilization.
Schaumberg D; Larholt K; Apgar E; Pashos CL; Hirsch G
Ther Innov Regul Sci; 2023 May; 57(3):472-475. PubMed ID: 36624361
[TBL] [Abstract][Full Text] [Related]
11. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials.
Foster NR; Qi Y; Shi Q; Krook JE; Kugler JW; Jett JR; Molina JR; Schild SE; Adjei AA; Mandrekar SJ
Cancer; 2011 Mar; 117(6):1262-71. PubMed ID: 20960500
[TBL] [Abstract][Full Text] [Related]
12. Combining tumour response and progression free survival as surrogate endpoints for overall survival in advanced colorectal cancer.
Elia EG; Städler N; Ciani O; Taylor RS; Bujkiewicz S
Cancer Epidemiol; 2020 Feb; 64():101665. PubMed ID: 31911395
[TBL] [Abstract][Full Text] [Related]
13. Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.
Wang X; Wang X; Hodgson L; George SL; Sargent DJ; Foster NR; Ganti AK; Stinchcombe TE; Crawford J; Kratzke R; Adjei AA; Kindler HL; Vokes EE; Pang H
Oncologist; 2017 Feb; 22(2):189-198. PubMed ID: 28188257
[TBL] [Abstract][Full Text] [Related]
14. Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers.
Ciani O; Davis S; Tappenden P; Garside R; Stein K; Cantrell A; Saad ED; Buyse M; Taylor RS
Int J Technol Assess Health Care; 2014 Jul; 30(3):312-24. PubMed ID: 25308694
[TBL] [Abstract][Full Text] [Related]
15. Objective response rate and progression-free survival as surrogates for overall survival treatment effect: A meta-analysis across diverse tumour groups and contemporary therapies.
Shahnam A; Hitchen N; Nindra U; Manoharan S; Desai J; Tran B; Solomon B; Luen SJ; Hui R; Hopkins AM; Sorich MJ
Eur J Cancer; 2024 Feb; 198():113503. PubMed ID: 38134560
[TBL] [Abstract][Full Text] [Related]
16. Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settings.
Hua T; Gao Y; Zhang R; Wei Y; Chen F
BMC Cancer; 2022 Sep; 22(1):1022. PubMed ID: 36171546
[TBL] [Abstract][Full Text] [Related]
17. Methods for the Inclusion of Real-World Evidence in a Rare Events Meta-Analysis of Randomized Controlled Trials.
Yao M; Wang Y; Mei F; Zou K; Li L; Sun X
J Clin Med; 2023 Feb; 12(4):. PubMed ID: 36836227
[TBL] [Abstract][Full Text] [Related]
18. Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative.
Franklin JM; Patorno E; Desai RJ; Glynn RJ; Martin D; Quinto K; Pawar A; Bessette LG; Lee H; Garry EM; Gautam N; Schneeweiss S
Circulation; 2021 Mar; 143(10):1002-1013. PubMed ID: 33327727
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of progression-free survival as a surrogate endpoint for survival in chemotherapy and targeted agent metastatic colorectal cancer trials.
Sidhu R; Rong A; Dahlberg S
Clin Cancer Res; 2013 Mar; 19(5):969-76. PubMed ID: 23303214
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]